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Abstract
Background—The National Breast and Cervical Cancer Early Detection Program (NBCCEDP) 
provides breast cancer screening to medically underserved, low-income women aged 40–64 years. 
No study has evaluated NBCCEDP’s effect on breast cancer mortality.
Purpose—This study estimates life-years saved by NBCCEDP breast cancer screening compared 
with screening in the absence of NBCCEDP and with no screening.
Methods—A breast cancer simulation model based on existing Cancer Intervention and 
Surveillance Modeling Network models was constructed. The screening module from these 
models was modified to reflect screening frequency for NBCCEDP participants. Screening data 
for uninsured women represented what would have happened without the program. Separate 
simulations were performed for women who received NBCCEDP (Program) screening, women 
who potentially received screening without the program (No Program), and women who received 
no screening (No Screening). The impact of NBCCEDP was estimated as the difference in life-
years between the Program and No Program, and the Program and No Screening scenarios. The 
analysis was performed in 2008–2009.
Results—Among 1.8 million women who were screened between 1991 and 2006, the Program 
saved 100,800 life-years compared with No Program and 369,000 life-years compared with No 
Screening. Per woman screened, the Program saved 0.056 life-years (95% CI=0.031, 0.081) 
compared with No Program and 0.206 life-years (95% CI=0.177, 0.234) compared with No 
Screening. Per woman with invasive breast cancer and screen-detected invasive cancer, the 
Program saved 0.41 and 0.71 life-years, respectively, compared with No Program.
Conclusions—These estimates suggest that NBCCEDP breast cancer screening has reduced 
mortality among medically uninsured and underinsured low-income women.
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Introduction
Breast cancer is the most commonly diagnosed cancer and the second-leading cause of 
cancer-related deaths among women in the U.S.1 Every year, more than 180,000 women are 
diagnosed with invasive breast cancer, resulting in more than 40,000 deaths.1 Studies2–9 
have demonstrated that mammography screening can reduce breast cancer mortality rates by 
15–30%. Because of mammography’s effectiveness in reducing breast cancer mortality, the 
U.S. Preventive Services Task Force (USPSTF), other medical organizations, and advocacy 
groups recommend breast cancer screening for women aged ≥40 years to receive screening 
mammography every 1–2 years.4,10–12 Recently, the USPSTF revised their earlier 
recommendation and recommended against routine screening mammography in women 
aged <50 years.13 The Task Force recommended that women in their 40s discuss with their 
physicians when to start getting mammograms.
Although mammography screening has demonstrated benefits in reducing breast cancer 
mortality; there is a concern that this recommendation may alienate certain segments of the 
population and further roll back some of the gains achieved in screening in the past decades. 
To date, these benefits have not been equally distributed among all women. Poor, uninsured, 
and underinsured women receive less screening than other groups.14 To reduce disparities in 
breast cancer mortality, the U.S. Congress passed the Breast and Cervical Cancer Mortality 
Prevention Act (Public Law 101-354) in 1990. This law gave the CDC the authority to 
establish and administer the National Breast and Cervical Cancer Early Detection Program 
(NBCCEDP).15 The program provides free or low-cost breast cancer screening to medically 
underserved women aged 40–64 years with an annual income ≤250% of the federal poverty 
level.16 In addition to screening services, NBCCEDP provides essential functions to reduce 
morbidity and mortality (e.g., quality assurance, case management, patient navigation, and 
connection to treatment) following a cancer diagnosis. Since 1991, NBCCEDP has provided 
more than 4.4 million breast screening examinations to more than 2.3 million women and 
has diagnosed more than 42,000 breast cancers.15
Though these accomplishments may have saved many lives, the program’s impact has not 
been quantified. Quantifying the benefits of mammography screening provided in 
NBCCEDP would be useful for allocating prevention resources in the program. The present 
study’s objective is to estimate the life-years saved by NBCCEDP breast cancer screening 
compared with screening in the absence of NBCCEDP and with no screening.
Methods
A breast cancer simulation model based on existing Cancer Intervention and Surveillance 
Modeling Network (CISNET) models17–20 was constructed. These models contain separate 
modules, including natural history, screening history, breast cancer mortality, early detection 
and treatment effects, and other-cause mortality. The screening module was modified to 
reflect screening frequency for women in NBCCEDP. A technical appendix (available online 
at www.ajpm-online.net) describes details of each of these modules and underlying 
parameters and assumptions. A brief explanation of each module is provided below. The 
analysis was performed in 2008–2009.
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Natural History
The natural history module determines whether invasive cancer will develop in a woman’s 
lifetime and, if so, when clinical detection will occur in the absence of screening. The 
probability of cancer developing and the age at clinical detection are based on CISNET 
estimates using Surveillance Epidemiology and End Results (SEER) breast cancer data.21 
These estimates approximate breast cancer incidence, stratified by age and birth cohort, in 
the absence of screening.
Screening
The screening history module generates a simulated screening history for each woman. The 
history generates the age of the first mammogram for each woman (some women never 
receive mammograms). The distribution of first screening and the probability of no 
screening depend on a woman’s age and birth cohort. Once a woman has had one 
mammogram, future intervals between mammograms are drawn from distributions that 
depend on whether the woman is an annual, biennial, or irregular screener. The women are 
randomly assigned to these categories, with the relative probabilities depending on age.
To determine whether breast cancer screening would lead to earlier detection, a breast cancer 
history and a screening history were generated for each woman. For women in whom cancer 
developed, the breast cancer history was overlaid with the screening history. If a screen 
occurred between the age when the tumor was screen detectable and the age at clinical 
detection, then the tumor would be detected early.
The modified model used CISNET data on the dissemination of mammograms in the general 
population.17,22 The CISNET base case code was obtained and modified to reflect the 
experience of NBCCEDP participants. NBCCEDP’s surveillance database was used to 
estimate both the women’s age at first mammography and the intervals between 
mammograms for women who participated in the program. National Health Interview 
Survey data from 1990–2005 was used to estimate mammography patterns among uninsured 
women to represent mammography screening in the program’s absence.
The Effects of Early Detection and Treatment on Breast Cancer Mortality
The goal of screening is to detect tumors earlier and subsequently provide appropriate and 
timely treatment. In the model, both early detection and treatment were incorporated in order 
to evaluate the impact of NBCCEDP. Mortality depends on age, stage, and tumor volume at 
the time the tumor is discovered. Thus, early detection with screening puts a woman on a 
more favorable survival curve by lowering tumor volume at discovery and potentially 
leading to an earlier stage at diagnosis. Survival is also affected by the type of treatment 
received (including adjuvant multiagent chemotherapy and tamoxifen), which depends on 
tumor stage at detection and estrogen receptor (ER) status. A woman is assumed to die from 
breast cancer if her age at detection plus her survival time is earlier than her estimated date 
of death from other causes.
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Mortality from Other Causes
Each woman is randomly assigned a date of death from other causes based on general U.S. 
mortality rates for 1950–2004. Breast cancer mortality is subtracted from the general 
mortality rates using methods developed by CISNET.23 A woman with breast cancer is 
assumed to die from other causes if her estimated date of death from other causes is earlier 
than her age at cancer detection plus her estimated survival time.
Calculation of Life-Years Saved
The analysis was limited to women who received mammograms covered by NBCCEDP 
between 1997 and 2006 because the NBCCEDP database was not complete prior to 1997. 
Using the screening history parameters, life-years saved by the program during the entire 
period from 1991 to 2006 and for their remaining lifetime were estimated.
Separate Monte Carlo simulations were performed for women who received screening 
through NBCCEDP (Program), women who potentially received screening without the 
program (No Program), and women who received no screening at all (No Screening). To 
estimate mean values and CIs for life-years saved, 1000 samples with 100,000 women per 
sample were simulated. To compare simulation results with real-world outcomes, simulation 
results were stated in terms of a population of 1.8 million women (i.e., the number of women 
who received mammograms through NBCCEDP between 1997 and 2006). The effect of 
NBCCEDP was estimated as the difference in life-years between the Program and No 
Program. This comparison reflects the fact that some uninsured women may receive 
mammogram screening even in the absence of NBCCEDP. To estimate the overall impact of 
screening, the difference in life-years between the Program and No Screening were 
calculated. A bootstrap approach was used to calculate 95% CIs for life-years saved, taking 
the 25th and 975th values from the 1000 samples. The model was programmed in TreeAge 
Pro 2008, version 1.5.1 (TreeAge Software Inc, Williamstown MA).
Sensitivity Analysis
Univariate sensitivity analyses were conducted from 2008 to 2009 to assess the impact of 
alternative assumptions about frequency of screening through the Program, the median 
diameter for screen detection, trends in breast cancer incidence, treatment efficacy, and the 
potential benefits from earlier clinical detection of cancers with symptoms through the 
Program. Each sensitivity analysis was based on 30 samples of 60,000 women.
Results
Based on the three simulation runs, women participating in NBCCEDP will receive 17.17 
screening mammograms over their lifetimes, compared with 12.38 screening mammograms 
in No Program scenario, and by definition, 0 screening mammograms in No Screening 
scenario (Table 1). Women who were eligible for the Program (aged 40–64 years) during at 
least some years of the period from 1991 to 2006 were estimated to receive 4.26 screenings 
with the Program compared with 2.44 screenings with No Program. Many women were 
eligible only during some of the period (e.g., a woman born in 1961 would be eligible from 
2001 to 2006 only). On average, actual NBCCEDP participants received 1.95 screenings 
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through the program, slightly higher than the estimated 1.82 screenings difference between 
the Program and No Program. The Program estimates include mammograms paid for by the 
program and mammograms received outside the program, so the difference between the 
Program and No Program scenario estimates represents the program’s incremental effect.
Slightly more invasive cancers are detected through screening or clinically with the Program 
than would be detected under the No Program and No Screening scenarios. The difference 
between the Program and No Screening scenarios represents tumors that are detected 
through screening that would not have been detected clinically until after the woman had 
died of other causes (e.g., a woman diagnosed at age 64 years in the Program may die from 
other causes at age 65 years; her tumor may not be evident prior to death in the No 
Screening scenario). About 57% (7.9%/13.8%) of the invasive cancers are screen-detected in 
the Program compared with about 46% (6.3%/13.8%) screen-detected in the No Program 
scenario. The estimated number of screen-detected cancers for women aged 40–64 years 
between 1991 and 2006 was 28,851 with the Program compared with 18,596 with No 
Program. The difference 10,255 approximates the 9037 invasive cancers detected among 
actual NBCCEDP participants who underwent nonsymptomatic screening during the period 
(Table 1).
In the Program scenario, 3.7% of women died of breast cancer compared with 4.0% and 
5.0% in the No Program, and No Screening scenarios, respectively. The average age at death 
was 80.57, 80.52, and 80.37 years for the Program, No Program, and No Screening 
scenarios, respectively (Table 1). The Program saved 100,800 life-years relative to No 
Program and 370,800 life-years relative to No Screening. Per woman screened, the Program 
saved 0.056 life-years (or 20.4 days) compared with No Program and 0.206 life-years (or 
75.2 days) compared with No Screening. Per woman with invasive breast cancer and screen-
detected invasive cancer, the Program saved 0.41 and 0.71 life-years, respectively, compared 
with No Program.
The 95% CI for life-years saved by the Program relative to No Program ranges from 0.031 
to 0.081 years, whereas the interval for the Program relative to No Screening ranges from 
0.177 to 0.234 years.
Sensitivity Analyses
Table 2 shows the results of one-way sensitivity analyses. Because the analyses were run for 
30 samples of 60,000 women, rather than the 1000 samples of 100,000 women in Table 1 
(due to run-time constraints), the main analysis estimate (0.061) in Table 2 is slightly 
different from the estimate (0.056) in Table 1. This difference, which is due to random 
variation, does not affect the qualitative results of the sensitivity analyses.
The main analysis assumes that substantially more women will be annual and biennial 
screeners through the Program than through No Program. If the Program advantage in 
annual and biennial screening is cut in half, the life-years saved by the Program declines to 
0.044. The life-years saved by the Program declines to 0.053 if all participating women 
receive biennial screening. Conversely, if all Program women receive annual screening, life-
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years saved increases to 0.089. This may be viewed as the greatest potential gain from 
screening through the Program.
In the main analysis, the median tumor diameter for screening detection was 10 mm. 
Increasing the median diameter to 15 mm reduced life-years gained from the Program to 
0.048. Conversely, if the median diameter for detection was 5 mm, life-years gained 
increased to 0.064. The reduction in tumor detection size will provide benefits only if 
screening occurs during the interval of time when the tumor’s diameter is between 5 and 10 
mm. The length of this interval depends on the tumor’s growth rate.
The analysis incorporates the increasing incidence of breast cancer between 1980 and 2000 
as suggested by CISNET. Slower rates of increase in the incidence of invasive cancer were 
also applied (or equivalently, larger percentages of ductal carcinoma in situ [DCIS] were 
subtracted). With lower incidence of invasive cancers, the difference in life-years between 
the Program and No Program scenarios declined moderately.
Model treatment effects are based on therapies available in 2000, and therapies may have 
improved over time. Several analyses assessed the effects of potential changes in treatment. 
When the mortality hazard was reduced by 10%, 20%, and 30% for both clinical and screen-
detected cancers, the difference in life-years saved between the Program and No Program 
scenarios fell to 0.057, 0.053, and 0.049 years, respectively.
The main analysis of Program benefits included life-years gained from early detection only. 
However, the Program may encourage uninsured women to seek care earlier when they 
experience symptoms of potential breast cancer, such as lumps or prolonged tenderness. 
This could lead to additional life-years saved if diagnosis and treatment for these clinically 
detected cancers begins earlier. The potential benefits that would occur if the Program 
allowed clinical detection to occur 1, 2, 3, or 6 months earlier were calculated. Adding 
benefits from clinically detected cancers would increase substantially the life-years saved by 
the Program. If clinical detection occurred 1 month earlier, the Program would save 0.090 
life-years, nearly 50% higher than the savings from screening detection only. Life-years 
increased even more when clinical detection occurred 2, 3, or 6 months earlier.
Discussion
This is the first study to estimate the effectiveness of NBCCEDP on breast cancer mortality 
measured by life-years saved due to screening over the past 15 years. Compared with No 
Screening, women screened through NBCCEDP gained 0.056 life-years per woman. 
Because the women diagnosed with breast cancer through NBCCEDP-sponsored screening 
programs are low-income, uninsured or underinsured, and less able to afford screening, these 
findings underscore the importance of organized screening programs such as NBCCEDP to 
the most vulnerable members of the population who are eligible for screening. Improving 
health for vulnerable members of the population by eliminating health disparities is one of 
the two overarching goals of the Healthy People 2010’s agenda for health promotion and 
disease prevention in the U.S.24
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At first glance, the estimated 0.056-life-year gain per woman in the Program might appear to 
be small. However, this population-based average of the 1.8 million women screened 
through the Program represents larger gains for women who actually develop breast cancer. 
The estimated Program gain for women in whom breast cancer develops is 0.41 life-years, 
and the gain for women in whom breast cancer is detected early through screening is 0.71 
life-years. The population average appears small because (1) breast cancer does not develop 
in seven of eight women; (2) screening detects only about 57% of cancers early; (3) some 
women in whom tumors are screen-detected early would have survived in the absence of 
screening; and (4) some women in whom tumors are screen-detected early still die. 
Averaging across all women also masks the large gains for women in whom cancers were 
screen-detected and who would have died of breast cancer in the absence of the Program. In 
a simulation of 100,000 women, 979 fell into this category, with an average gain of 11.33 
life-years.
Comparing results described in this report with other national prevention programs is 
difficult because study methods, target population ages, and disease characteristics differ. 
Regardless of these differences, Table 3 shows expected improvements in life-years from 
selected population-based prevention programs25 and the estimates for life-years saved by 
NBCCEDP. The table provides some perspective as well as consistency for the results. On a 
per-person basis, an earlier study25 reported gain in life-years for 10 years of biennial 
mammography screening starting at age 50 years to be 0.067, which is consistent with the 
present study’s results. Breast cancer screening through NBCCEDP gains fewer life-years 
than stopping smoking (0.056 vs 0.67–0.83 life-year per person) but more life-years than 
childhood immunization vaccines, such as measles and rubella (0.008 life-year each). 
Further, a recent regression-based modeling study examined the impact of NBCCEDP on 
breast cancer mortality rates and found that there is some evidence to suggest that 
NBCCEDP has led to a reduction in breast cancer mortality rates, which is also consistent 
with the present study’s results.26
The analysis has some limitations. First, the results are based on a simulation model rather 
than clinical trial results or a long-term, follow-up study of health outcomes for program 
participants. A clinical trial of NBCCEDP is unlikely for ethical reasons. Currently, long-
term, follow-up data are not collected on women who receive NBCCEDP screening. Second, 
the analysis assumes that NBCCEDP participants in whom cancers are detected receive the 
same treatment as women in the general population. Although complete treatment data on 
NBCCEDP participants are not collected, program data confirm that most women with a 
diagnosis of breast cancer begin definitive treatment. Since 2000, nearly all women 
diagnosed through the program have been eligible for immediate enrollment in Medicaid, 
wherein complete treatment is provided free.
Third, the results show only life-years gained and do not include gains from reductions in 
morbidity, which would increase the quality-adjusted life-years (QALYs) gained by 
NBCCEDP. For most cancers, however, QALYs gained are largely determined by life-years 
gained.27 On the other hand, the analysis does not include harm arising from false positives 
or overdiagnosis (the identification of tumors that would never have become a clinical 
problem in the patient’s lifetime), which might reduce the QALYs gained. Fourth, the main 
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analysis includes only life-years saved by screening mammograms. As the sensitivity 
analyses show, life-years saved would be higher if access to the Program led to earlier 
clinical diagnosis for women who seek screening in response to breast cancer symptoms. 
However, data to accurately simulate symptomatic screening were lacking.
Fifth, the NBCCEDP’s database is incomplete before 1997. Therefore, the analysis focused 
on women who received at least one NBCCEDP mammogram between 1997 and 2006. 
Available earlier data on these women were used to estimate the benefits they received for 
the entire period between 1991 and 2006. The estimates may underestimate the total life-
years saved by the Program because the approach excluded women who received Program 
screenings between 1991 and 1996 only. Sixth, NBCCEDP may help uninsured women gain 
access to the healthcare system, leading to better care for conditions besides breast and 
cervical cancer. For instance, the Well-Integrated Screening and Evaluation for Women 
Across the Nation (WISEWOMAN)28 program provides heart disease and stroke screening 
to women who enter NBCCEDP. The analysis includes only the direct effects of NBCCEDP 
on breast cancer survival. Finally, the analysis focuses on the effects of NBCCEDP 
screening. Breast cancer outcomes depend on other public health initiatives, including 
programs to reduce obesity, lower smoking rates, and increase awareness of breast cancer 
and screening guidelines. These initiatives are not explicitly modeled in the analysis.
These limitations notwithstanding, the estimates of life-years saved suggest that the 
collective efforts of NBCCEDP grantees, policymakers, and other national partners to offer 
breast cancer screening to medically underserved, low-income populations have had 
substantial impact in reducing mortality from breast cancer for these populations. For 
researchers, these results can be used to estimate the cost effectiveness of breast cancer 
screening in this population. For policymakers, the findings in this article are encouraging 
and may be useful for allocating resources in the program. Currently, less than 15% of 
women eligible for NBCCEDP receive mammography screening from the program.29 If the 
number of women served by the program increases, life-years saved will increase 
proportionately. Alternatively, medically underserved low-income women may gain better 
access to life-saving cancer screening services through implementation of the Affordable 
Care Act.
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Table 3
Life years saved by selected preventive services
Intervention Target population
Gain in life expectancy (life-
years)
Quitting cigarette smoking 35-year-olds 0.667–0.833
Pap, every year for 55 years 20-year-old women 0.267
Annual fecal occult blood test, plus barium enema or colonoscopy 50-year-olds 0.183–0.208
10 years of biennial mammography 50-year-old women 0.067
NBCCEDP (Program vs No Program) Low-income, uninsured women, aged 
40–64 years
0.056
Measles vaccine Infants 0.008
Rubella vaccine Infants 0.008
Source: NBCCEDP: present study. All other interventions: Wright and Weinstein, 1998.25
NBCCEDP, National Breast and Cervical Cancer Early Detection Program
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